Sunkyu Kim

American International Group (United States) — United States

Medicine · Health Sciences

41h-index13.6kcitations197works7.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(29), Advanced Breast Cancer Therapies(19), Cancer-related Molecular Pathways(16), Lung Cancer Research Studies(15), Computational Drug Discovery Methods(13)

Publications189 total

Discovery of INCB126503 as a Potent and Selective FGFR2/3 Inhibitor
ACS Medicinal Chemistry Letters·2025· 4 cited
Abstract 3789: INCB177054: A novel, potent, orally bioavailable DGKα/ζ dual inhibitor enhances T-cell function and demonstrates potent antitumor activity
Cancer Research·2025· 4 cited
Abstract 4185: A novel USP1 inhibitor enhances PARP inhibitor efficacy in elevated replication stress tumors: Evidence from BRCA-mutant and CCNE1-amplified models
Cancer Research·2025
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Journal of Medicinal Chemistry·2025· 9 cited
BADGER: biologically-aware interpretable differential gene expression ranking model
Bioinformatics Advances·2024Open Access
Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer
JCO Clinical Cancer Informatics·2024· 3 cited
A retrospective analysis of conception per embryo transfer in dairy cattle in South Korea
Theriogenology·2024· 3 cited
Research on Evaluating and Improving the Dedicated Fixture Manufacturing Process for Water-Jet Robot Machining
Korea Industrial Technology Convergence Society·2024
Abstract 5900: INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in <i>KRAS G12D</i> mutant tumors
Cancer Research·2024· 11 cited
Abstract 7149: Discovery of a novel USP1 inhibitor: Targeted therapy for BRCA-mutated and PARPi-resistant cancers
Cancer Research·2024
Abstract 3324: Discovery of a novel SOS1 inhibitor, AIG01012, targeting pan-KRAS mutant cancers
Cancer Research·2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2
Journal of Medicinal Chemistry·2024· 14 citedOpen Access
Large Language Models: A Comprehensive Guide for Radiologists
Journal of the Korean Society of Radiology·2024· 3 citedOpen Access
Large Language Models: A Guide for Radiologists
Korean Journal of Radiology·2024· 67 citedOpen Access
Exploring Quality Differentiation between Open and Garage Parking: Evidence from Gimpo International Airport
SSRN Electronic Journal·2024Open Access
Enhancing Clinical Outcome Predictions through Auxiliary Loss and Sentence-Level Self-Attention
2023· 1 cited
ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib
Blood·2023· 5 cited
Comparison of the Enzymatic and Cellular Profiles of Clinical JAK2 Inhibitors for the Treatment of Myelofibrosis
Blood·2023· 5 cited
Preclinical Evaluation of INCB160058 - a Novel and Potentially Disease-Modifying Therapy for JAK2V617F Mutant Myeloproliferative Neoplasms
Blood·2023· 15 cited
Evaluation of crowdsourced mortality prediction models as a framework for assessing artificial intelligence in medicine
Journal of the American Medical Informatics Association·2023· 8 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Jaewoo Kang(16), Minji Jeon(7), Chi V. Dang(5), Giordano Caponigro(5), Christopher T. Brain(5), Alice Loo(5), Kyubum Lee(5), Aik Choon Tan(5), Sung‐Joon Park(5), William R. Sellers(4), Sudha Parasuraman(4), Rajiv Chopra(4), Sunwon Lee(4), Byeong Jae Lee(4), Heewon Lee(4), Donghyeon Kim(3), Qing Li(3), Linda A. Lee(3), Lori S. Hart(3), Andrew Wood(3)